Skip to main content

Leukemia, lymphoma, and myeloma.

83 Phase 1 studies recruiting right now, most recently updated first.

Open the Phase 2 page · a list of only those studies

Triangle is made by Triangle Health, Inc.

Leukemia, lymphoma, and myeloma83 studies

Acute Myeloid Leukemia and Myelodysplastic SyndromePhase 1NCT07283094Papers

FHD-286

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

Montefiore Medical CenterOpen the brief

Relapsed/Refractory B-Cell Non-Hodgkin LymphomaPhase 1NCT06209619

CC-99282 + Rituximab

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Nathan DenlingerOpen the brief

Newly Diagnosed Acute Myeloid LeukemiaPhase 1NCT05558124

CPX-351 + Gemtuzumab Ozogamicin

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

H. Lee Moffitt Cancer Center and Research InstituteOpen the brief

Relapsed or Refractory Large B-Cell LymphomaPhase 1NCT05755087

Tegavivint

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Lapo AlinariOpen the brief

Relapsed/Refractory Acute Myeloid LeukemiaPhase 1/2NCT05580601

CIML-NK Cells

Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

Children's Hospital Medical Center, CincinnatiOpen the brief

Relapsed or Refractory Chronic Lymphocytic LeukemiaPhase 1/2NCT06644183

Roginolisib + Venetoclax and Rituximab

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD, PhDOpen the brief

Relapsed/Refractory Multiple MyelomaPhase 1NCT07093554

Talquetamab

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Medical College of WisconsinOpen the brief

B-cell Acute Lymphoblastic LeukemiaPhase 1NCT06559189Papers

CD19x22 CAR T

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

University of Colorado, DenverOpen the brief

Acute Lymphoblastic Leukemia, AdultPhase 1/2NCT03676504Papers

CD19.CAR T Cells

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

University Hospital HeidelbergOpen the brief

Clinical trials: Phase 1 and Phase 2, explained